All > Liver Cirrhosis > Pulmonary Fibrosis

68Ga-FAP-2286 for Pulmonary Fibrosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Pulmonary Fibrosis+2 More68Ga-FAP-2286 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help researchers learn if FAP-2286 can be used to help identify different types of fibrosis and if it is safe for human use.

Eligible Conditions
  • Pulmonary Fibrosis
  • Liver Fibrosis
  • Myocardial Fibrosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
68Ga-FAPi-46
1
Gallium Ga 68-DOTATATE
1
Gallium Ga 68 FAPi-46

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: Up to 31 days

Up to 1 days
Median peak standardized uptake value (SUV) in myocardium region
Liver
Lung
Up to 31 days
Proportion of participants with treatment-related adverse events

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
68Ga-FAPi-46
1
Gallium Ga 68-DOTATATE
1
Gallium Ga 68 FAPi-46

Trial Design

3 Treatment Groups

Cohort 1: Liver Fibrosis
1 of 3
Cohort 2: Pulmonary Fibrosis
1 of 3
Cohort 3: Myocardial Fibrosis
1 of 3

Experimental Treatment

30 Total Participants · 3 Treatment Groups

Primary Treatment: 68Ga-FAP-2286 · No Placebo Group · Phase 1

Cohort 1: Liver FibrosisExperimental Group · 2 Interventions: 68Ga-FAP-2286, Positron Emission Tomography (PET) · Intervention Types: Drug, Procedure
Cohort 2: Pulmonary FibrosisExperimental Group · 2 Interventions: 68Ga-FAP-2286, Positron Emission Tomography (PET) · Intervention Types: Drug, Procedure
Cohort 3: Myocardial FibrosisExperimental Group · 2 Interventions: 68Ga-FAP-2286, Positron Emission Tomography (PET) · Intervention Types: Drug, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography (PET)
2019
Completed Phase 4
~1320

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 31 days

Who is running the clinical trial?

Clovis Oncology, Inc.Industry Sponsor
62 Previous Clinical Trials
10,301 Total Patients Enrolled
Thomas HopeLead Sponsor
8 Previous Clinical Trials
1,589 Total Patients Enrolled
Thomas A Hope, MDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
499 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Cohort 2: Pulmonary fibrosis, based on CT findings or biopsy of lung parenchyma.
You are able to understand and sign a written informed consent document.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top